IS5331A - Ný lyfjablanda - Google Patents

Ný lyfjablanda

Info

Publication number
IS5331A
IS5331A IS5331A IS5331A IS5331A IS 5331 A IS5331 A IS 5331A IS 5331 A IS5331 A IS 5331A IS 5331 A IS5331 A IS 5331A IS 5331 A IS5331 A IS 5331A
Authority
IS
Iceland
Prior art keywords
new pharmaceutical
pharmaceutical mix
mix
new
pharmaceutical
Prior art date
Application number
IS5331A
Other languages
English (en)
Other versions
IS2439B (is
Inventor
Broadhead Joanne
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of IS5331A publication Critical patent/IS5331A/is
Publication of IS2439B publication Critical patent/IS2439B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5331A 1997-07-11 1999-12-30 Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar IS2439B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (2)

Publication Number Publication Date
IS5331A true IS5331A (is) 1999-12-30
IS2439B IS2439B (is) 2008-11-15

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5331A IS2439B (is) 1997-07-11 1999-12-30 Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar

Country Status (36)

Country Link
US (1) US6130208A (is)
EP (1) EP1000079B1 (is)
JP (1) JP4950380B2 (is)
KR (1) KR100786654B1 (is)
CN (2) CN1864696A (is)
AR (1) AR013157A1 (is)
AT (1) ATE340801T1 (is)
AU (1) AU8362598A (is)
BR (1) BR9810703A (is)
CA (1) CA2295628C (is)
CY (1) CY1105805T1 (is)
CZ (1) CZ298110B6 (is)
DE (1) DE69836023T2 (is)
DK (1) DK1000079T3 (is)
EE (1) EE04119B1 (is)
ES (1) ES2273425T3 (is)
HK (1) HK1026429A1 (is)
HU (1) HU226489B1 (is)
ID (1) ID24716A (is)
IL (2) IL133868A0 (is)
IS (1) IS2439B (is)
MY (1) MY116421A (is)
NO (1) NO329918B1 (is)
NZ (1) NZ502073A (is)
PL (1) PL192768B1 (is)
PT (1) PT1000079E (is)
RU (1) RU2216330C2 (is)
SA (1) SA98190328B1 (is)
SE (1) SE9702680D0 (is)
SI (1) SI1000079T1 (is)
SK (1) SK285766B6 (is)
TR (1) TR200000006T2 (is)
TW (1) TW585764B (is)
UA (1) UA65576C2 (is)
WO (1) WO1999002542A1 (is)
ZA (1) ZA985669B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986281B2 (ja) * 2004-10-05 2012-07-25 旭化成ファーマ株式会社 補酵素の安定化方法およびその組成物
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
ES2470329T3 (es) 2009-08-28 2014-06-23 Daiichi Sankyo Company, Limited Derivado del ácido 3-(biariloxi) priopi�nico
ES2773040T3 (es) 2009-11-11 2020-07-09 Chiesi Farm Spa Métodos de tratamiento o prevención de trombosis de stent
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2013025697A1 (en) 2011-08-17 2013-02-21 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
CA2819548C (en) * 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
AU2012214396B2 (en) 2011-02-09 2017-04-27 Chiesi Farmaceutici S.P.A. Methods for treating pulmonary hypertension
ES2904256T3 (es) 2013-03-09 2022-04-04 Chiesi Farm Spa Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MX2017009289A (es) 2015-01-14 2017-10-11 Chiesi Farm Spa Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
CA3060345A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
HRP20240071T1 (hr) 2018-06-19 2024-03-29 Ucb Pharma Gmbh Piridinil-(aza)indolsulfonamidi

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (is) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
CA2155673C (en) * 1993-02-10 2004-08-17 Anthony Howard Ingall N-alkyl-2-substituted atp analogues
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
EE200000022A (et) 2000-10-16
HU226489B1 (en) 2009-03-02
IL133868A (en) 2010-05-17
AR013157A1 (es) 2000-12-13
IS2439B (is) 2008-11-15
PL337970A1 (en) 2000-09-11
CA2295628C (en) 2008-07-29
ES2273425T3 (es) 2007-05-01
WO1999002542A1 (en) 1999-01-21
NZ502073A (en) 2001-09-28
DE69836023D1 (de) 2006-11-09
CN1864696A (zh) 2006-11-22
JP4950380B2 (ja) 2012-06-13
CY1105805T1 (el) 2011-02-02
MY116421A (en) 2004-01-31
SI1000079T1 (sl) 2007-08-31
HUP0002622A3 (en) 2002-04-29
ATE340801T1 (de) 2006-10-15
HUP0002622A2 (hu) 2001-05-28
RU2216330C2 (ru) 2003-11-20
UA65576C2 (uk) 2004-04-15
CA2295628A1 (en) 1999-01-21
AU8362598A (en) 1999-02-08
PL192768B1 (pl) 2006-12-29
ID24716A (id) 2000-08-03
CN1263533A (zh) 2000-08-16
US6130208A (en) 2000-10-10
DK1000079T3 (da) 2006-11-20
SE9702680D0 (sv) 1997-07-11
EP1000079B1 (en) 2006-09-27
CZ200083A3 (cs) 2000-06-14
NO20000123L (no) 2000-03-03
BR9810703A (pt) 2000-08-08
CZ298110B6 (cs) 2007-06-27
IL133868A0 (en) 2001-04-30
HK1026429A1 (en) 2000-12-15
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
TW585764B (en) 2004-05-01
NO329918B1 (no) 2011-01-24
NO20000123D0 (no) 2000-01-10
JP2001509512A (ja) 2001-07-24
SK183699A3 (en) 2000-07-11
TR200000006T2 (tr) 2000-07-21
PT1000079E (pt) 2006-12-29
SA98190328B1 (ar) 2006-08-15
ZA985669B (en) 1999-01-11
EP1000079A1 (en) 2000-05-17
KR100786654B1 (ko) 2007-12-21
EE04119B1 (et) 2003-08-15
KR20010021647A (ko) 2001-03-15

Similar Documents

Publication Publication Date Title
DE59806590D1 (de) Gemischabgabevorrichtung
NO20001776L (no) Medikamenter
DE59806604D1 (de) Gemischabgabevorrichtung
ID24654A (id) Formulasi farmasi omeprazola
DE69716887D1 (de) Mischer
IS4974A (is) Lyfjasamsetning á þrýstingsúðaformi
DE69814786D1 (de) Mischer
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
DE69818280D1 (de) Homogenisierventil
NO980546D0 (no) Farmasöytiske midler
NO994003L (no) Farmasoytisk blanding
NO20000857D0 (no) Mikseapparat
IS5331A (is) Ný lyfjablanda
DK1017392T3 (da) Lægemiddel
ID27150A (id) Sediaan levotiroksin bahan farmasi
EE9900545A (et) Farmatseutiline kompositsioon
NO994619D0 (no) Farmasöytiske blandinger
MA26531A1 (fr) Composition pharmaceutique
NO20003141D0 (no) Farmasøytiske blandinger
EE9800209A (et) Antiglükokortikoidne ravimaine
ID23531A (id) Komposisi farmasi
FR2760978B1 (fr) Melangeur vertical
ATA16897A (de) Betonmischung
BR1100755A (pt) composição farmacêutica
ATA61598A (de) Rührgerät